06:51 EST Viatris (VTRS) doesn’t see FDA warning impacting current 2024 financial guidance
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Viatris confirms receipt of warning letter, import alert for India facility
- Viatris announces publication of CARE study results
- Viatris Elects Directors and Amends Stock Plan at Meeting
- Viatris price target raised to $14 from $13 at Piper Sandler
- Viatris price target raised to $12 from $11 at Barclays